Clinical trials: Myelogenous Leukemia, Acute
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
This is an open label, prospective, single institution dose-escalation study. The patient population includes non-induction candidate elderly patients with AML or MDS and/or patients with high-risk or relapsed/refractory AML or…
- Trial name
- NCT00892190
- Testing
- dasatinib (SPRYCEL), all trans retinoic acid (VESANOID)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pittsburgh
Myeloid Leukemia, Acute
Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments
This study aims to analyze patients with mutated FLT3 AML treated with specific therapy by means of molecular characterization methods, to identify the presence of clones and subclones at onset and to be able to follow their…
- Trial name
- CLEV-LAM-2022 (NCT06764459)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Leukemia
Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
The purpose of this study is to evaluate both the efficacy and toxicity of infusional arsenic trioxide in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APML).
- Trial name
- NCT00008697
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
Myelodysplastic Syndromes, Leukemia Acute Myeloid
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
patients with MDS (Myelodysplastic Syndrome) and mutated IDH2 patients will be treated with AG221 (IDH2 inhibitor)
- Trial name
- NCT03744390
- Testing
- AG-221
- Where
- 22 sites in France
- Volunteers
- 68 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Myelogenous Leukemia, Acute
A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
This multi-center, open-label, Phase 1b study will evaluate the safety, pharmacokinetics and efficacy of RO5045337 in combination with cytarabine in patients with acute myelogenous leukemia.
- Trial name
- NCT01635296
- Testing
- RO5045377, cytarabine
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Acute Promyelocytic Leukemia
Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy
This is a prospective and international observational study run by the GIMEMA. All data will be centrally collected and analyzed at the GIMEMA Data Center in Rome (Italy).
- Trial name
- NCT03096496
- Testing
- QoL questionnaires
- Where
- 16 sites in Italy
- Volunteers
- 161 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
AML (Acute Myeloid Leukemia)
FLT3-ITD Targeted Therapy in Fit AML Patients
This international, multicenter, randomized (1:1), open-label phase II/III trial will evaluate the efficacy and safety of gilteritinib combined with azacitidine and venetoclax (experimental arm) versus standard "7+3" induction…
- Trial name
- FIT-AML (NCT07425808)
- Testing
- Gilteritinib, Venetoclax, Azacitidine (AZA)
- Volunteers
- 230 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia, First Line Therapy
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid…
- Trial name
- NCT06928376
- Testing
- Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, "3+7"
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Chinese PLA General Hospital
Acute Myeloblastic Leukemia
LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
Prospective, multicenter, uncontrolled cohort study to analyze the efficacy of a risk adapted treatment strategy, including gemtuzumab ozogamicin (GO) during consolidation, for patients with acute myeloid leukemia (AML).
- Trial name
- NCT01041040
- Testing
- gemtuzumab
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- PETHEMA Foundation
Relapsed/Refractory Acute Myeloid Leukemia
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
The purpose of this study is to determine if a combination of nintedanib+ induction chemotherapy can be an effective strategy for patients where outcome of relapse/refractory acute myeloid leukemia (AML) is poor.
- Trial name
- NCT02665143
- Testing
- Nintedanib and AML induction
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Yale University
ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia
Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
Umbilical cord blood (UCB) is rich in haematopoietic stem progenitor cells and immune cells, and is used for transplantation for a variety of haematological disorders with the advantages of low mating requirements and fewer…
- Conditions
- ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia, MDS (Myelodysplastic Syndrome)
- Trial name
- NCT07297576
- Testing
- Sulforaphane
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia
A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia
This was an open-label pilot study that evaluated the safety and preliminary evidence of a therapeutic effect of dociparstat in conjunction with standard induction and consolidation therapy for acute myeloid leukemia (AML).
- Trial name
- PGX-AML (NCT02056782)
- Testing
- Dociparstat sodium
- Volunteers
- 12 people
- Sponsor
- Jazz Pharmaceuticals
Acute Myeloid Leukemia
D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
With the aging of society, the incidence of elderly leukemia in China has been increasing year by year. The elderly patients with Acute Leukemia have poor basal state, and there are many important organ diseases such as heart…
- Trial name
- NCT04168138
- Testing
- rhTPO
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Huihan Wang
Chronic Myeloid Leukemia, Myelodysplastic Syndrome
Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established form of treatment for hematological abnormalities. Poor graft function, occurs when there poor donor engraftment.
- Conditions
- Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
- Trial name
- NCT02258490
- Testing
- G-CSF mobilized CD34+ selected cells for transplantation
- Where
- United States
- Sponsor
- Emory University
AML, Adult
Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage.
- Trial name
- RAPID-01 (NCT06138990)
- Testing
- Pharmacoscopy, Clinical standard-of-care (physician's choice)
- Where
- 2 sites in Switzerland
- Volunteers
- 88 people
- Sponsor
- ETH Zurich
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
Haploidentical hematopoietic stem cell transplantation irrespective of the conditioning intensity and graft-versus-host disease prophylaxis is associated with high frequency of primary and secondary graft failure.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma
- Trial name
- NCT06477549
- Testing
- Bendamustine Hydrochloride, Ruxolitinib
- Where
- Russia
- Volunteers
- 220 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Acute Myeloid Leukemia (AML)
Assessing Refractoriness and Infectious Survival Events in AML
Despite therapeutic advance in acute myeloid leukemia (AML), the prognosis remains poor, with an overall survival (OS) of 30% at 5 years [1, 2].
- Trial name
- ARISE-AML (NCT06709235)
- Where
- France
- Volunteers
- 280 people
- Sponsor
- Hospices Civils de Lyon
Acute Myeloid Leukemia
Harnessing the Immunosuppressive Leukemic Microenvironment to Engineer T Cells With Enhanced Anti-tumor Functionality
This is a monocentric, retrospective and prospective study aimed to underline the potential of T-cell receptor (TCR)-mediated Ab recognition from the post transplant setting in acute myeloid leukemia (AML).
- Trial name
- SynT (NCT07743047)
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
AML, Acute Myeloid Leukemia
Cardioprotection in AML
Patients with acute myeloid leukemia (AML) often receive a drug called daunorubicin. Daunorubicin is a type of drug called an anthracycline, which increases the risk of some damage to the heart.
- Trial name
- AML 001 (NCT04977180)
- Testing
- Cardioprotection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Virginia
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00935090
- Testing
- 3'-deoxy-3'-[18F]fluorothymidine
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.